隽泰控股2024中期报告

INTERIM REPORT中 期 報 告2024 Contents Management Discussion and Analysis2Corporate Governance and Other Information11Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income18Interim Condensed Consolidated Statement of Financial Position19Interim Condensed Consolidated Statement of Changes in Equity20Interim Condensed Consolidated Statement of Cash Flows21Notes to the Interim Condensed Consolidated Financial Statements22 Management Discussion and Analysis管理層討論及分析 RESULTS, BUSINESS REVIEW AND PROSPECTS Results For the six months ended 30 June 2024, AMCO United Holding Limited(the“Company”)and its subsidiaries(collectively referred to as the“Group”) are principally engaged in (i) manufacture and sale of medicaldevices products (“Medical Products Business”); (ii) manufacture and saleof plastic moulding products (“Plastic Products Business”); (iii) provisionof money lending (“Money Lending Business”); and (iv) investment insecurities (“Securities Investment”). (i)(ii)(iii)(iv) Duringthe period under review,revenue of the Group amounted toHK$22.0million,representing a decrease of HK$1.3 million or 5.6%fromHK$23.3 million for the corresponding period last year.Suchdecrease was mainly attributable to the decrease in revenue from theMedical Products Business and Plastic Products Business. 22,000,00023,300,0001,300,0005.6% Gross profit of the Group was HK$6.8 million, representing an increaseofHK$1.9 million or 38.8%as compared to HK$4.9 million for thecorrespondingperiod last year.Gross profit margin increased by 9.7percentage points to 30.8% (30 June 2023: 21.1%). 6,800,0004,900,0001,900,00038.8%9.730.8%21.1% 22,900,00020,300,000 Other losses, net of other income and other gains, during the periodunderreview recorded loss of HK$22.9 million as compared to lossof HK$20.3 million in the corresponding period of 2023. The amountincluded realised and unrealised fair value gain/(loss) of held-for-tradinginvestments arising from Securities Investment and the change of fairvalue on financial liabilities at fair value through profit or loss in thecurrent period. Management Discussion and Analysis管理層討論及分析 The distribution costs decreased by HK$0.5 million to HK$2.2 millionduringthe period under review(30 June 2023:HK$2.7 million),alongside with the decrease in revenue of MedicalProducts BusinessandPlastic Products Business.The administrative expenses decreasedby HK$4.2 million to HK$5.9 million (30 June 2023: HK$10.1 million),representing a decrease of 41.6% over the corresponding period lastyear, primarily as a result of the decrease in general administrative costsunder stringent cost control during the current period. 5 0 0 , 0 0 02 , 2 0 0 , 0 0 02,700,0004,200,0005,900,00010,100,00041.6% Financecosts amounted to HK$1.2 million(30 June 2023:HK$1.4million) for the period under review, which represented interest on bondpayables. 1,200,0001,400,000 25,400,00029,700,0004,300,000 As a result, the overall loss attributable to owners of the Company wasHK$25.4 million, which decreased by HK$4.3 million as compared toHK$29.7 million loss for the corresponding period of 2023. Business Review Medical Products Business 16,300,00016,400,00074.2% For the six months ended 30 June 2024, the revenue from the MedicalProducts Business remain stable which amounting to HK$16.3 million,as compared to revenue of HK$16.4 million recorded in the same periodlast year, which accounted for 74.2% of the Group’s total revenue forthe period under review. In the first half of 2024, the sales demandofMedical Products Business remain stable although there is keencompetition in the industry. Management Discussion and Analysis管理層討論及分析 Segment profit of the Medical Products Business amounted to HK$1.7million for the six months ended 30 June 2024, as compared to segmentprofit of HK$1.4 million in the corresponding period last year. To copewith the challenge of fluctuating sales order, the Group is persisting todeploy business strategies of streamlining and outsourcing of businessprocesses,implementing strict cost control and ensuring effectiveutilisation of resources with an aim to maintain its long-term sustainablecompetitiveadvantages in the business segment.In the meantime,theGroup is actively exploring and identifying potential businessopportunities to expand its customer base and also the products andservicesportfolio of the business segment in order to generate andbroaden the income streams of the Medical Products Business. 1,700,0001,400,000 Plastic Products Business 600,000600,0000% The revenue from the Plastic Products Business decreased by HK$0.6million to HK$Nil million for the six months ended 30 June 2024, ascompared to HK$0.6 million in the corresponding period last year, whichaccounted for 0% of the Group’s total revenue for the period underreview. The decrease mainly attributable to the decrease in sales orderdue to keen competition in the industry. Management Discussion and Analysis